Kun for helsepersonell
Menu
Close
Hair growth takes time and patients may respond differently
Patients should be counselled not to stop taking LITFULO without discussing with their doctor
LITFULO should be taken once a day, every day
If treatment interruption is needed, the risk of significant loss of regrown scalp hair after a temporary interruption (<6 weeks) is low
The benefit-risk of treatment should be reassessed at regular intervals on an individual basis. Consideration should be given to discontinuing patients who show no evidence of therapeutic benefit after 36 weeks of treatment with LITFULO
Preparatomtale
Pfizer AS, Org.nr 915 213 596
Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo
Tlf.: +47 67 52 61 00
PP-BCP-NOR-0001 juni 2023
Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.